Skip to content
Niacin
Niaspan, Nicolar, Wampocap (niacin) is a small molecule pharmaceutical. Niacin was first approved as Wampocap on 1982-01-01. It is used to treat hypercholesterolemia, hypertriglyceridemia, pellagra, and peripheral vascular diseases in the USA. It is known to target hydroxycarboxylic acid receptor 3, hydroxycarboxylic acid receptor 1, hydroxycarboxylic acid receptor 2, and carbonic anhydrase 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Niacin
Tradename
Company
Number
Date
Products
NIASPANAbbVieN-020381 DISCN1997-07-28
4 products, RLD
NIASPAN TITRATION STARTER PACKAbbVieN-020381 DISCN1997-07-28
1 products
WAMPOCAPMedpointe Pharm HlcN-011073 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
derma pella luminous creamunapproved drug other2023-06-20
niacorANDA2021-12-23
niaspanNew Drug Application2013-08-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypercholesterolemiaHP_0003124D006937—
hypertriglyceridemiaEFO_0004211D015228—
pellagra—D010383—
peripheral vascular diseasesEFO_0003875D016491I73.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C04: Peripheral vasodilators
— C04A: Peripheral vasodilators
— C04AC: Nicotinic acid and derivatives, peripheral vasodilators
— C04AC01: Nicotinic acid
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AD: Nicotinic acid and derivatives, lipid modifying, plain
— C10AD02: Nicotinic acid
— C10AD52: Nicotinic acid, combinations
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA01: Lovastatin and nicotinic acid
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNIACIN
INNnicotinic acid
Description
Nicotinic acid is a pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group. It has a role as an antidote, an antilipemic drug, a vasodilator agent, a metabolite, an EC 3.5.1.19 (nicotinamidase) inhibitor, an Escherichia coli metabolite, a mouse metabolite, a human urinary metabolite and a plant metabolite. It is a vitamin B3, a pyridinemonocarboxylic acid and a pyridine alkaloid. It is a conjugate acid of a nicotinate.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(O)c1cccnc1
Identifiers
PDB6MBV
CAS-ID59-67-6
RxCUI7393
ChEMBL IDCHEMBL573
ChEBI ID15940
PubChem CID938
DrugBankDB00627
UNII ID2679MF687A (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HCAR3
HCAR3
HCAR1
HCAR1
HCAR2
HCAR2
CA2
CA2
Organism
Homo sapiens
Gene name
HCAR3
Gene synonyms
GPR109B, HCA3, HM74B, NIACR2
NCBI Gene ID
8843
Protein name
hydroxycarboxylic acid receptor 3
Protein synonyms
G-protein coupled receptor 109B, G-protein coupled receptor HM74, G-protein coupled receptor HM74B, GTP-binding protein, hydroxy-carboxylic acid receptor 3, Niacin receptor 2, Nicotinic acid receptor 2, putative chemokine receptor
Uniprot ID
Q8NGE4
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Niaspan - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 91,983 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
42 adverse events reported
View more details